In a recent series of 568 patients with NPM1-mutated AML treated with intensive chemotherapy, those harboring MRGs had significantly decreased event-free survival (EFS) and a higher probability of MRD-positive disease at the end of induction [101]. The gene discussed is NPM1; the disease is acute myeloid leukemia.